How a California startup became a global powerhouse in the world of biotechnology

How a California startup became a global powerhouse in the world of biotechnology
Image: Intellect (generated)

In short: Founded in 1980 as Applied Molecular Genetics, Amgen evolved from a small venture-backed experiment into a biopharmaceutical giant. Today, it dominates the industry with blockbuster treatments for bone disease, cancer, and inflammation, while pioneering the use of artificial intelligence to accelerate the discovery and manufacturing of life-saving medicines.

Amgen began in Thousand Oaks, California, in April 1980, initially focusing on recombinant DNA technology and human insulin. Under the leadership of its first CEO, George Rathmann, and a scientific advisory board featuring experts like Leroy Hood, the company quickly established its research credentials. By 1983, it had gone public, raising nearly $40 million. A major breakthrough arrived that same year when a team led by Fu-Kuen Lin successfully cloned the erythropoietin gene, which stimulates red blood cell production, eventually leading to the 1989 approval of Epogen.

The company's growth strategy has relied heavily on both internal innovation and strategic acquisitions. Throughout the 1990s and 2000s, Amgen expanded its manufacturing footprint globally, including sites in Puerto Rico and Ireland. Its portfolio now includes high-revenue products like Prolia, XGEVA, and Repatha. In recent years, Amgen has aggressively expanded its rare disease pipeline, notably acquiring Horizon Therapeutics in 2023 for $27.8 billion and ChemoCentryx in 2022 for $3.7 billion. These moves complement a robust clinical pipeline that currently features 17 programs in Phase III trials.

Innovation at Amgen is increasingly driven by advanced technology. In 2023, the company partnered with Amazon Web Services to integrate artificial intelligence into its drug discovery and manufacturing workflows. This digital shift mirrors its earlier scientific milestones, such as the development of Lumakras, the first targeted therapy for KRAS-mutated cancers. Today, Amgen remains a cornerstone of the biomedical sector, ranked 134th on the Fortune 500 and included in the Dow Jones Industrial Average since 2020, while maintaining a complex distribution network that relies on three major U.S. wholesalers for approximately 80% of its revenue.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

  • Summary by Intellect · source: Amgen

To cite this card, link to https://intellectplus.co.uk/app/technology-amgen.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…